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ABSTRACT: 
The emergence of biotechnology is one of the most important changes in the health innovation 
systems. This paper discusses the rationale that has supported the public policies oriented to boost 
health biotechnology development in Brazil during 2004 and 2014. Based on a thorough revision of 
policy documents and on an extensive fieldwork, the study highlights the accumulative path followed 
by the Brazilian public policies. This research shows how these policies followed an uneven 
accumulative path were several rationales cohabited integrating explicit and implicit policies. Finally, the 
boundaries of policy action are discussed, stressing two critical dimensions that delimit the scope of 
policy action: i) the change of policy orientation and rationale, ii) that pose new governance’s 
challenges, which, in turn require new coordination with other implicit policies. 
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owadays, several studies draw the attention to the growing capabilities of some developing 
countries in health biotechnology (Thorsteinsdóttir 2012; Göranson & Pålsson 2011). 
Among them, the Brazilian case has been regarded as one of the new players in the 
production of healthcare solutions based on biotechnology research (Rezaie et al. 2008). 
Brazil has a small but significant amount of firms devoted to human health biotechnologies as 
well as a large accumulation of scientific capabilities in this field (Torres Freire 2014). During the period 
2004-2014, the Brazilian innovation and productive policies stressed the strategic relevance of 
biotechnology as a tool to deal with national health challenges as well as to promote new knowledge 
based activities.  
Based on international experiences and in the evolution of the Brazilian health biotech 
innovation policies, this paper revisits earlier analysis of the public policies devoted to health biotech in 
Brazil (Bianchi 2013a) discussing the policy rationale. The paper deals with two main question: What 
has the rationale of biotech policy been? Has the theoretical basis of these policy rationales changed? 
The general hypothesis states that several rationales cohabit during the period 2004-2014 
supporting different objectives and instruments. Even though this process has been erratic, it allows the 
emergence of adequate institutional solutions to deal with some of the most relevant challenges of the 
Brazilian health biotechnology system. 
The second section presents a brief revision of the theoretical basis of the Brazilian 
biotechnology policy rationale. The general hypothesis states that this rationale is based on theoretical 
ideas built on the experiences of developed countries, mostly built on the United State (US) 
biotechnology industry. In section three the Brazilian Health Biotechnology Innovation System 
(BHBIS) is analyzed contrasting its most significant features to some stylized facts of the U.S. health 
biotechnology innovation system. This comparison allows stressing the intermediate mechanisms 
operating in each case and particularly, to point out the relative importance of market and state 
mechanisms. Finally, the conclusions discuss the boundaries of public policy action, by analyzing how 
some systemic features delimit the potential action of policies. 
1. A POLICY RATIONALE: WHAT ARE THE THEORETICAL ASSUMPTIONS BEHIND POLICY 
PROGRAMS? 
From a static point of view, a biotechnology health system is defined as a web of relationship 
in which different types of agents and institutions participate in working on the biotechnology health 
development process. It involves government agencies in charge of public policy design and research 
funding, research institutions, public and private firms fully or partially devoted to biotechnology, 
N 
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healthcare institutions, and intermediary institutions dedicated to link different agents and support 
innovative biotechnology activities.  
Complementing this vision from a dynamic approach implies the analysis of how this web of 
relationship changes through time, varying its size and functions (Dodgson et al. 2008). The aim of this 
paper is to discuss how a specific feature of the Brazilian health biotechnology innovation systems 
changed in the period 2004-2014. It refers to the public policies oriented to promote the health 
biotechnology development and, specifically to the rationale of these policies. The general hypothesis 
states that national public policies oriented to boost the development of health biotechnology in Brazil 
has been based on the expectation to reproduce some stylized patters of the U.S. experience. 
1.1. HUMAN HEALTH BIOTECHNOLOGY: AND OPERATIVE DEFINITION 
Although there are several debates about what modern biotech is and what is not, there are 
more coincidences than differences related to the biotechnology technical definition (Fonseca 2009; 
Orsenigo 1989; Pisano 2006; Hopkins et al. 2007). Regarding the coincidences, biotechnology is 
defined in this paper as a body of knowledge and a comprehensive set of procedures and technologies 
that analyses the attributes of the cells allowing the molecules, DNA and proteins to create or modify 
products or processes for specific uses with various applications.  
Even using a general definition of biotechnology, several authors contend that there is not an 
evident definition of biotechnology in the health sector, because of the variety of biotechnological, 
chemical and bioinformatics techniques that are introduced into health related industries. In this regard, 
there are different operative definitions, which have been proposed according to the specific objective 
of each research, but there is not a consensual definition. Taking into account this discussions, this 
work follows a wide definition of health biotechnology that embraces the discovery of therapeutic 
agents that are used in healthcare as well as rational drug design, drug delivery systems, and 
manufacturing of drugs, serum, vaccine and others biotech developed products (Niosi & Reid 2007). 
1.2. THE EVOLUTION OF MODERN HEALTH BIOTECHNOLOGY INDUSTRY: FROM THEORY TO 
POLICY MODELS 
The history of the upsurge of biotech in the industrial health complex, especially in the 
pharmaceutical industry, has been widely exposed by several authors. This history has always been 
related to the experienced of developed countries, mainly U.S. Rather than recalling the history once 
again, this section is focused on three stylized facts of the widespread theoretical explanations on this 
process (Bianchi 2013a).  
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i) Modern biotechnology has changed the health innovation process; 
ii) While small dedicated biotech firms (DBF) emerge from science-production 
relationships, the incumbent big pharmaceutical firms follow different diversification 
strategies; 
iii) The market mechanisms functioning works under a new institutional dynamic 
characterized by venture financial systems and intellectual property right (IPR) 
regulation. 
Several authors stressed that the advent of modern biotechnology creates a new knowledge 
basis has been changing the drug innovation process (Gadelha 1990; McKelvey et al. 2004; Pammolli et 
al. 2011). This change has happened while new linkages between research organizations and firm arose. 
The development process of new therapeutic solutions requires strong linkages with scientific research 
(Brännback et al. 2009; McMillan et al. 2000; Kneller 2010). It shows a systemic dynamic where the 
scientific research activities influence in the goods and services health production while a growing 
influence of the industrial criteria in the scientific production is perceived (Orsenigo 1989; Pisano 
2006). It implies successive ramification of knowledge, from some general questions to emerge new 
specific hypothesis oriented to solve the development of a new drug for a new problem. The 
emergence of new problems is the results of the new discovery process in a successive solved problem 
chain (Orsenigo et al. 2001). 
These changes boosted the appearance of new small and medium enterprises (SMEs) devoted 
to biotechnology creating different inter-firm relationships and different business models (Mangematin 
et al. 2003; Audretsch & Feldman 2003). While the biotechnology health innovations emerge from 
SMEs and research centers, the big pharmaceutical firms adopted different strategies of diversification 
of the technological basis and product portfolio (Mittra 2007; Gutman & Laravello 2010)-in the initial 
stages- a strategy of wait and see to know the potential impact of the new emergent technologies 
(Hopkins et al. 2007).  
On the other hand, at the same time that new firms entering in the market with a significant 
impact on the industrial structure, it is possible to observe a market concentration process led by the 
big firms. This process was promoted by market and institutional factors, but mainly by the structural 
features that are inherent to the health related industry. It has traditionally been a monopoly or 
oligopoly industry. In the case of pharmaceutical, the market works as an oligopoly segmented 
according to different therapeutic classes. Moreover, it is a market where the main products –ethical 
medicines- have low price elasticity, new firms find high barriers to entry (Caravaglia et al. 2006) 
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Finally, all these transformations were accompanied by institutional changes creating a 
"market of ideas" through venture financial systems and intellectual property right regulation (Pisano 
2006; Coriat et al. 2003).  
Figure 01. Anatomy of the US Health Biotech System 
 
Source: adapted from: Pisano (2006:81). 
Figure 1 was adapted from Pisano (2006) and –with a few adaptations- shows the stylized 
characteristics of the US Biotech Health System. It emphasizes the relevance of the IPR regime as well 
as the capital markets, which are regarded as the key institutions that make the existence of market 
knowledge possible. That market is the base for the entrance of new firms and to start the selective 
process which is not smooth and, in fact, is plenty of uncertainty.  
Several authors state the importance of these aspects to explain the singular characteristics of 
US biotech health system. The behavior of the start-up firms in U.S. highlights the relative advantages of 
cooperation as SMEs’ commercial strategy, are related to the existence of a specific regulatory 
framework. Early in the nineties the US Congress Office for Technology Assessment (OTA), stated 
that biotechnology firms that surged in US, could only be replicated in a similar regulatory environment 
and with the support of a mature capital market (OTA 1991). These are the aspects that sustain the 
question: “Does biotech reflect a new science-based innovation regime?” made by Coriat et al. (2003) in order to 
analyze the US biotech innovation system. These authors classified the U.S. biotech health system as a 
new variety of innovation regime based on science, which integrated itself new specific regulatory and 
financial institutions, adapted according to the technological specificities of the new regime. 
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After a relative long period were economics studies on biotechnology were focused on 
developed countries, a growing accumulation on biotechnology innovation system in developing 
countries has appeared (Göransson & Pålsson 2011; Guennif & Ramani 2012). Many of them show the 
differences between a specific national case and the previous accumulation on the experience of 
developed countries (Kang & Park 2012; Dodgson et al. 2008; Reid & Ramani 2012; Gutman & 
Lavarello 2010) Meanwhile, other studies analyzed the biotechnological evolution in developing 
countries comparing with developed countries' experience (Thorsteinsdóttir et al. 2004; Niosi et al. 
2012. Abuduxike & Aljunid 2012). However, less attention has been paid to the role of public policies 
and specifically to their rationales (Guennif & Ramani 2012. Vargas & Bianchi 2013). 
Within this general landscape, a singular case is India. This is a national case which has been 
studied from the role of policies, its evolution, supporting actors and rationale (Ahn et al. 2012; 
Watkins et al. 2015; Reid & Ramani 2012; Ramani 2002). These works stress the significance of the 
State's role in the Indian biopharmaceutical development, and how it was linked to a national strategy 
of gradual learning to became a global player in the biopharmaceutical market (Kale & Huzair 2015). 
Considering this background, the general hypothesis of this paper states that many features of 
the U.Ss health biotechnology system have been taken as a policy model in the Brazilian public policies 
oriented to promoted health biotechnology. It is particularly clear through the relevance given in the 
national explicit policies to create new dedicated biotechnology firms (DBF) and to boost patents of 
new molecules through university-firm collaboration agreements (Governo Federal 2007 & 2008). 
These policy objectives was presented almost as the normal way to develop commercial health 
biotechnology. However, at the same time, public effort were also oriented to boost the national 
pharmaceutical industry (Palmeira et al. 2012; Pimentel et al. 2013). 
In this point it is worth revisited the concept of implicit and explicit innovation policies 
(Herrera 1973; Galhardi 1994). The later refer to scientific, technological, innovation or industrial 
policies which explicitly pursue an effect on the biotechnology development. On the other hand, the 
implicit policies could be any other public policy that implicitly affect the biotechnology development. 
Typical examples are macroeconomic policies which affect, in one or another sense, the agents’ 
decisions; i.e. the investment decision. In the case of the Brazilian health biotechnology, the more 
important implicit policy is the national health policy, which regulate the demand and delivery of most 
health service in Brazil. The universal healthcare system is one of the most relevant social pacts in the 
Brazilian society after the democracy recovery (Vargas 2009). The BHBIS cannot be understood 
without considering the Brazilian universal healthcare system. 
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The second hypothesis of this paper states that the Brazilian health biotechnology policies 
have been incorporated new policy models both from developed and developing countries. Many of 
these changes implied a growing concern with demand side policies and public private productive 
agreement rather than the earlier concern with firm creation and intellectual property rights.  
The analysis of the BHBIS is conducted in a comparative and dynamics way. In this regard, 
the U.S. experience allows a useful comparison to analyze the institutional policy specificities of the 
BHBIS. Based on the thorough revision of public document and in an extensive fieldwork of 
interviews, this research stresses the difference between the BHBIS and the U.S. Health Biotechnology 
Innovation System. It makes possible to analyze the policy rationale and how it has evolved. The period 
of analysis was defined considering two criteria. First, in 2004 the new orientation of developmental 
policies was initiated through the launching of the Industrial, Technology and Foreign Trade Policy 
(Governo Federal 2003) both science, technology and innovation policies and industrial policies. In 
addition, the analysis end in 2014 because it marks the beginning of the contractive phase of the 
economic cycle, which can affect the policy design and rationale. 
2. THE BRAZILIAN HEALTH BIOTECH SYSTEM 
The economical and policy features of health biotechnologies in Brazil has been widely 
studied during the last 30 years (Anciães & Cassiolato 1985; Guimarães & Vianna 1994; Sant'Ana & 
Aucélio 2006; Torres-Freire 2014). Brazil has a long research tradition on life science strongly related 
with medical research and clinic (Weltman 2002). Moreover, there is a significant amount of research 
groups currently working in modern biotechnology (Bianchi 2012) and there is a small but dynamic 
number of firms fully or partially dedicated to produce biotechnological products or service for human 
health (Torres Freire 2014). However, the BHBIS is still weak, particularly regarding cooperation 
efforts. Inter firm and public private firm collaboration have only recently gained relevance (Chu & 
Andreassi 2011).  
In the last years new and more accurate information about health biotech in Brazil has been 
produced (BRBIOTEC 2011; Torres Freire 2014; Bianchi 2012 & 2013b; Reis et al. 2010). Even 
though, the landscape of the BHBIS is still incomplete, it is possible to analyze the main features of five 
key actors: i) dedicated biotechnological firm; ii) incumbent diversified firm, iii) the State as policy 
maker and regulator; iv) the research institutions and v) the intermediate institutions (Figure 2). 
The number of firm fully or partially devoted to health biotech is not exactly known but, the 
most recent sources show that there are around 50 active firms working on modern biotechnology for 
human health (Torres Freire 2014; Bianchi 2013b). Within the private productive agents, there are 
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incumbent firm, which diversified their production incorporating biotechnological products, and new 
DBF. The diversified firms are mostly traditional pharmaceutical companies.  
The Brazilian pharmaceutical industry has traditionally been a knowledge receptor and a 
producer of traditional goods. Some of them have shown a innovative pathways. However, it is still a 
traditional industry. Arguably, one of the main weakness of the Brazilian health related industries is the 
dependency on imported intermediate inputs, even ones that the local industry is able to produce 
(ANVISA 2012; ABIQUIFI 2011). This was a structural feature throughout the nineties, accumulating 
a millionaire trade sectoral deficit (Capanema et al. 2008; Vargas & Bianchi 2013). In this situation, 
Brazilian biotechnological policies, both form innovation and industrial side as well as form the health 
side, pointed out the great challenge to take the advantage of biotechnology to boost national 
production. Recently, some big national firms, which had followed a strategy of “wait and see”, are 
investing in new plants, incorporating biotechnology technicians’ teams and production project in this 
area (Vargas 2009). In addition, new public private agreements have been carried out pursuing an 
increase in national production (Vargas & Bianchi 2013).  
Regarding the creation and development of DBF, earlier works stressed that the biotech 
development in Brazil is strongly associated to local factors. The main development poles of BHBIS 
are in the southeast region, mainly in Minas Gerais (MG) and Sao Paulo (SP). Both cases show strong 
research capabilities and dynamic intermediary institutions. Nevertheless, Fonseca (2009) distinguished 
between the patterns followed by these states, stressing that in MG prevailed a Science Park Model, based 
on the relationship university-enterprise, and in the upsurge of several start-up firms from the four 
Federal Universities located at this State that conduct biotech research programs. In this case, the role 
performed by the Biobrás has had a demonstration effect (Cassiolato et al. 2011). This author notes 
that in MG university-industry relationships led to a model based on business incubators and start-ups, 
while SP experience can be characterized as a network-based model. Arguably the best example of this 
model was the Projeto Genoma. This project presents a typical network-model, composed by more than 
twenty laboratories along all the country and involving hundreds of researchers. Despite the remarks 
posed above about the scarce results that the genome project reached in the production of new 
healthcare methods this experience was the base for a networking process between several research 
institutes and biotech firms located in SP.  
A general feature is that, with varying intensity, every biotechnological firms have strong ties 
of cooperation with universities or research institutes and with foreign institutions. But there are few 
experiences of collaboration between local biotechnological firms (Rezaie et al. 2008).  
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On another hand, the Brazilian State is a key actor of the BHBIS. It not only acts as a policy 
maker and regulator. Indeed the State acts as healthcare services provider, drug producer and buyer. 
Particularly, the role of public laboratories both in R&D and production activities is one of the basis of 
the BHBIS (Costa et al. 2014). 
Comparing figure 1 and 2, the BHBIS presents the same mains actors as the US biotech 
system. Nevertheless, there are clear differences in the development of capital markets and IPR regime. 
This does not imply that the BHBIS does not have financial instruments, but they are mostly 
concentrated on the public agencies. In Brazil, even the ventures capitals funds are composed by state 
owned firms that operate in private regime. 
Figure 02. Brazilian Health Biotechnology Innovation System. 
 
Source: Own elaboration. 
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Moreover, the other institutions that compose the BHBIS do not bear great “anatomic” 
differences when compared to US’s. The differences are mostly found on the operation of the system 
rather than on its composition. 
As Figure 2 shows, the BHBIS presents a different level of development (size of grey area) in 
each of their actors and a relatively weak development in the linkages among the agents. The central 
circles expose the dynamic dimension of the BHBIS: the expected results, that have been not fully 
achieved yet. There are many studies that stress a critical diagnosis of the BHBIS (Cassiolato et al. 2011. 
Marques & Gonçalves Neto 2007. Rezaie et al. 2008). The critical remarks are mainly related to the 
micro and meso dimensions of Brazilian system, such as regulation and management innovation 
dimensions. In addition, some authors stressed the disappointment of firm's managers with some 
public programs that show an academic research bias (Barbosa et al. 2007). 
In this sense, several agents stressed the relative low private sector development and to the 
gap between research capabilities and innovation results. Actually, this is one of the patterns that 
characterize the biotech development in the peripheral countries is the major strength in the phase of 
generation of knowledge –research and discovery- rather than in product development and 
commercialization (Quach et al. 2006). In this general frame, SMEs entrance in the market is relatively 
easy -through science-push strategies-, but then they found strong difficulties to achieve and conserve a 
market position as final or intermediate product suppliers. 
3. THE BOUNDARIES OF POLICIES  
The stylized facts of the BHBIS presented in this paper show many of the goals pursued by 
public policies during the last decade. To understand the evolution of the policies and their rationale it 
is relevant considering that any policy is a deliberate effort to impact on economics and society which 
may confront with several problems through its implementation which, in turn, limit their effectiveness 
and potentially undermine its legitimacy (Giesecke 2000).  
The limits that the Brazilian health biotechnology policy confronts can be analyzed considering 
two main dimensions related to the evolution of policies: i) the change of policy orientation and 
rationale, ii) that pose new governance’s challenges, which, in turn require new coordination with other 
implicit policies.  
Even though the evolution of public policies between 2004 and 2014 has been erratic and 
even uneven, there is a significant change in the rationale of policies. Since the PITCE proposal until 
the most recent measures of Public Private Partnership, policies have pursued the explicit goal of 
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coordinate productive, commercial and technological policies. However, at the beginning of the period 
this objective was mainly pursued through instruments oriented to create a private supply of biotech, 
mainly by new DBF and patents. Recently, a demand side policies, articulated with the healthcare goals 
have been implemented though the public private partnership.  
This change, involve a complex transformation on the policy rational that only was partially 
presented in this paper. Dealing with complexity require high capabilities and more fluent governance 
resources. 
The governance’s problems are related to the basic features of biotechnology. Since it is a 
technology area rather than a economy sector, health biotechnology cannot be pigeonholed in the 
classical sectoral government structure, for instance, in only a sectoral ministry. It is not a problem, it is 
mostly a challenge; and probably it is not a new one. Coordination difficulties are as old as the public 
policy. Nevertheless, it establishes a serious limit to the effectiveness of policies.  
Regarding the BHBIS, public governance have to deal with sectoral goals organized in an 
horizontal manner, mainly to coordinate with the implicit policies of the Healthcare System. Arguably, 
one of the more relevant aspects regarding public policy effectiveness is related to its coherence with 
other policies. Recent effort have been focused on health technological public procurement and public 
private partnership that include pre-commercial public procurement commitment.  
Governance problems, basic resource and the articulation of different policies are 
undoubtedly very important to understand the effectiveness of the policies. However, the real limits of 
the policies are established by the behavior and preferences of the economic agents, specifically by the 
firms’ behavior. Every policy documents begin with a chapter which exposes the motives that justify 
the initiative. All of them make –implicit or explicit- reference to the general interest and their 
relationship with individual benefits, and all of them try to change some kind of organization or 
behavior in order to pursue the general interest. Obviously, it is very difficult to agree about what the 
general interest is, and even more complicated is to agree on how to achieve it.  
As is well known, policies are based on several assumptions about the agent behavior. The 
limit of the policies exists because –fortunately- the policies cannot impose rigid rules to the behavior's 
agent. Then, they can propose incentives to promote or inhibit determined actions.  
It is probable that the great difficulties resulting from the combination of social, innovation 
and industrial policies in a technical environment in permanent change, would lead to new changes In 
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this regard, the Brazilian health biotechnology policies face strong limits, but the evolution of the 
BHBIS appears mostly dependent on the state strategy rather than strong local market mechanisms 
The limits that can found the policies are well known in developing countries. Nowadays, 
biotechnology has a relevant place in the public agenda in many of them. This fact shows the 
expectation to pursue the windows of opportunity that are opening by the emergent technologies. 
Nevertheless, this hope may end in frustration if the complex dimensions that intermediate between 
policy design and their effective application are not taken into account. 
Finally, as Hopkins et al. (2007) highlight the analysis of these kinds of intermediate problems 
is a specific issue of the social science research, whose investigators has the responsibility of promoting 
realistic public expectations, avoiding the association of the biotech paradigm with magical solutions. 
This is particularly relevant for the underdeveloped countries, which should not find new frustrations in 
the implementation of development strategies. This does not mean that the technological opportunities 
should be always regarded as myths or as frustrations. It is clear that the promises of a biotech 
revolution may be taken with caution by countries with a weak industrial infrastructure. 
REFERÊNCIAS 
ABIQUIFI 2011. Produção local de moléculas ajudará a reduzir déficit. Um olhar sobre o mundo 81. 2-3. 
Rio de Janeiro. Available from: http://abiquifi.org.br/publicacoes/umolhar/um_olhar_81.pdf  
Abuduxike G, Aljunid S M, 2012. Development of health biotechnology in developing countries: Can 
private-sector players be the prime movers?. Biotechnology advances, 30(6), 1589-1601. 
Ahn M J, Hajela A, Akbar M, 2012. High technology in emerging markets: Building biotechnology 
clusters, capabilities and competitiveness in India. Asia-Pacific Journal of Business Administration, 4(1), 23-
41. 
Anciães W. Cassiolato J.E. 1985. Biotecnologia seus impactos no setor industrial. CNPq. Brasília. 
ANVISA 2012. Relatório inspeção internacional de fabricantes de insumos farmacêuticos ativos. 
COISC/GIMEP/ANVISA, Brasília. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/ 
e5208b804df45861897dbbc09d49251b/RELATORIO+INSPE%C3%87%C3%83O+INTERNACIO
NAL+INSUMOS+-Vers%C3%A3o+Final+-+21-12-2012.pdf?MOD=AJPERES  
Audretsch D, Feldman M, 2003. Small-firm strategic research partnerships: The case of biotechnology. 
Technology analysis & strategic management, 15(2), 273-288. 
Barbosa A, Mendes R, Sennes R, 2007. Avaliação da Política Industrial, Tecnológica e de Comércio 
Exterior para o setor Farmacêutico. Estudos Febrafarma 13. 
Bianchi C, 2012 Grupos de pesquisa em biotecnologia moderna no Brasil: uma revisão sobre os 
fundamentos da política de CTI. Revista Iberoamericana de Ciencia, Tecnología y Sociedad. 7(21), 23-43. 
Brazilian Health Biotechnology Innovation System: an essay about the public policy rationale 
 
Carlos Bianchi 
 
 
Fronteiras: Journal of Social, Technological and Environmental Science • http://revistas.unievangelica.edu.br/index.php/fronteiras/  
v.5, n.1, jan.-jun. 2016 • p. 14-30. • DOI http://dx.doi.org/10.21664/2238-8869.2016v5i1.p14-30 • ISSN 2238-8869 
26 
 
Bianchi C, 2013a The role of innovation policies in the Brazilian health biotechnology regime. Latin 
American Business Review 14 (3-4), 309–332. 
Bianchi C, 2013b A Indústria Brasileira de Biotecnologia: montando o quebra-cabeça. Revista Economia 
& Tecnologia. 9(2), 99-116.. 
Brännback M, Carsrud A, Renko M, Östermark R, Aaltonen J, Kiviluoto N, 2009. Growth and 
profitability in small privately held biotech firms: Preliminary findings. New biotechnology, 25(5), 369-376. 
BRBIOTEC 2011. Brazil Biotech Map 2011. BRBIOTEC-CEBRAP , São Paulo. Available from: 
http://www.cebrap.org.br/v1/upload/pdf/Brazil_Biotec_Map_2011.pdf  
Capanema L, Palmeira P, Pieroni J, 2008. Apoio do BNDES ao Complexo Industrial da Saúde: a 
experiência do PROFARMA e seus desdobramentos. BNDES Setorial, Rio de Janeiro, 27, 3-20,. 
Cassiolato J, Zucoloto G, Rapini M, Antunes S, 2011. The recent evolution of the Biotech local 
innovation system of Minas Gerais: university, local firms and transnational corporations, in B 
Göransson, C Pålsson, (Eds) Biotechnology and Innovation Systems. The Role of Public Policy. Edward Elgar 
Publishing. p. 13-57. 
Chu D, Andreassi T, 2011. Management of technological innovation: Case studies in biotechnology 
companies in Brazil. Management Research: Journal of the Iberoamerican Academy of Management, 9(1), 7-31. 
Coriat B, Orsi F, Weinstein O, 2003. Does Biotech Reflect a New Science-based Innovation Regime? 
Industry & Innovation, 10(3) 231 – 253. 
Costa L S, Gadelha C, Maldonado J, Santo M, Metten A, 2014. O complexo produtivo da saúde e sua 
articulação com o desenvolvimento socioeconômico nacional. Revista do Serviço Público, 64(2), 177-199. 
Dodgson M, Mathews J, Kastelle T, Hu M, 2008. The evolving nature of Taiwan's national innovation 
system: The case of biotechnology innovation networks. Research Policy, 37(3), 430-445 
Ferrer M, Thorsteinsdóttir H, Quach U, Singer P, Daar A, 2004. The scientific muscle of Brazil’s health 
biotechnology. Nature Biotechnology, 22(12), DC8–DC10. 
Fonseca M G, 2009 Documento Setorial: Biotecnologia Projeto Perspectivas do Investimento no Brasil. 
Sistema Produtivo: Baseados em ciência. BNDES. UFRJ. Unicamp. Rio de Janeiro. 
Gadelha C, 1990 Biotecnologia em Saúde: um estudo da mudança tecnológica na indústria farmacêutica e das 
perspectivas de seu desenvolvimento no Brasil. Master dissertation. IE – UNICAMP, Campinas. 
Galhardi R M, 1994. Brazilian policy for biotechnology: a critical review. Science and Public Policy, 21(6), 
395-403. 
Gans J S, Hsu D H, Stern S, 2002. When does start-up innovation spur the gale of creative destruction? 
RAND Journal of Economics, 33(4), 571-586. 
Garavaglia C, Malerba F, Orsenigo L, 2006. Entry, market structure, and innovation in model of the 
evolution of the pharmaceutical industry, in M Mazzucato & G Dosi, G. Knowledge Accumulation and 
Industry Evolution The Case of Pharma-Biotech. Cambridge University Press 
Brazilian Health Biotechnology Innovation System: an essay about the public policy rationale 
 
Carlos Bianchi 
 
 
Fronteiras: Journal of Social, Technological and Environmental Science • http://revistas.unievangelica.edu.br/index.php/fronteiras/  
v.5, n.1, jan.-jun. 2016 • p. 14-30. • DOI http://dx.doi.org/10.21664/2238-8869.2016v5i1.p14-30 • ISSN 2238-8869 
27 
 
Giesecke S, 2000. The contrasting roles of government in the development of biotechnology industry 
in the US and Germany. Research Policy, 29(2), 205-223. 
Göransson B, Pålsson C, (Eds) 2011 Biotechnology and Innovation Systems. The Role of Public Policy. Edward 
Elgar Publishing. 
Governo Federal 2003 Diretrizes de Política Industrial, Tecnológica e de Comércio Exterior. MDIC Brasília. 
Available from: http://www.anped11.uerj.br/diretrizes.pdf  
Governo Federal 2007. Política de Desenvolvimento da Biotecnologia. ABDI, Brasilia. Available from: 
http://www.abdi.com.br/Paginas/comunidade_politica.aspx?c=Comit%C3%AA%20Nacional%20de
%20Biotecnologia  
Governo Federal 2008. Política de Desenvolvimento Produtivo MDIC, Brasília. Available from: 
http://www.mdic.gov.br/pdp/index.php/sitio/inicial  
Guennif S, Ramani S V, 2012. Explaining divergence in catching-up in pharma between India and 
Brazil using the NSI framework. Research Policy, 41(2), 430-441. 
Guimarães R, Vianna C, 1994. Ciência e tecnologia em saúde: tendências mundiais, diagnóstico global e estado da 
arte no Brasil. In: Anais da I Conferência Nacional de Ciência e Tecnologia em Saúde p. 115-236. 
Gutman G, Lavarello P, 2010. Desarrollo Reciente de la Moderna Biotecnología en el Sector de Salud Humana. 
Documentos de Trabajo del CEUR 3/2010. CEUR-CONICET. Available from: http://www.ceur-
conicet.gov.ar/imagenes/MBenSHDocumento2.pdf  
Herrera A, 1973. Los determinantes sociales de la política científica en América Latina. Política 
científica explícita y política científica implícita. Desarrollo Económico 13 (49), 113-134. 
Hopkins M, Martin P, Nightingale P, Kraft A, Mahdi S, 2007. The myth of the biotech revolution: An 
assessment of technological, clinical and organisational change. Research Policy 36 (4), 566–589.  
Kale D, Huzair F, 2015. New sources of growth under the TRIPS compliant patent regime for emerging country 
pharmaceutical industries?: Investigating the development of biosimilar capabilities in the Indian pharmaceutical sector. 
In: 13th Globelics International Conference, Havana, Cuba. 
Kang K N, Park H, 2012. Influence of government R&D support and inter-firm collaborations on 
innovation in Korean biotechnology SMEs. Technovation, 32(1), 68-78. 
Kneller R, 2010. The importance of new companies for drug discovery: origins of a decade of new 
drugs. Nature Reviews Drug Discovery, 9(11), 867-882. 
Mangematin V, Lemarié S, Boissin J, Catherine D, Corolleur F, Coronini R, Trommetter Mm 2003. 
Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France. Research 
Policy, 32(4), 621-638. 
Marques R, Gonçalves Neto C, 2007. The Brazilian System of Innovation in Biotechnology: a 
preliminary study. Journal of Technology Management & Innovation, 2(1). 55-63 
Brazilian Health Biotechnology Innovation System: an essay about the public policy rationale 
 
Carlos Bianchi 
 
 
Fronteiras: Journal of Social, Technological and Environmental Science • http://revistas.unievangelica.edu.br/index.php/fronteiras/  
v.5, n.1, jan.-jun. 2016 • p. 14-30. • DOI http://dx.doi.org/10.21664/2238-8869.2016v5i1.p14-30 • ISSN 2238-8869 
28 
 
McKelvey M, Rickne A, Laage-Hellman J, 2004 Stylized facts about innovation processes in modern 
biotechnology, in: M McKelvey, A Rickne, J Laage-Hellman,. (Eds) The Economic Dynamics of Modern 
Biotechnology Edward Elgar Cheltenham, UK 43 - 75 
McMillan G S, Narin F, Deeds D L, 2000. An analysis of the critical role of public science in 
innovation: the case of biotechnology. Research Policy, 29(1), 1-8. 
Mittra J, 2007 Life science innovation and the restructuring of the pharmaceutical industry: Merger, 
acquisition and strategic alliance behaviour of large firms. Technology Analysis & Strategic Management, 
19(3), 279-301. 
Niosi J, Hanel P, Reid S, 2012. The international diffusion of biotechnology: the arrival of developing 
countries. Journal of Evolutionary Economics, 22(4), 767-783. 
Niosi J, Reid S, 2007. Biotechnology and Nanotechnology: Science-based Enabling Technologies as 
Windows of Opportunity for LDCs? World Development 35(3) 426–438. 
Orsenigo L, 1989. The emergence of biotechnology. Pinter Publishers, London. 
Orsenigo L, Pammolli F, Riccaboni M, 2001. Technological change and network dynamics. Lessons 
from the pharmaceutical industry. Research Policy 30(3). 485–508 
OTA 1991 Biotechnology in a Global Economy. U.S. Congress, Office of Technology Assessment, OTA-
BA-494. Government Printing Office. Washington, DC: U.S.A. 
Palmeira P, Pieroni J, Antunes A, Bomtempo J, 2012. O desafio do financiamento à inovação 
farmacêutica no Brasil: a experiência do BNDES Profarma. Revista do BNDES 37, 67-90. 
Pammolli F, Magazzini L, Riccaboni M, 2011. The productivity crisis in pharmaceutical R&D. Nature 
reviews Drug discovery, 10(6), 428-438. 
Pimentel V, Gomes R, Landim A, Maciel M, Pieroni J P, 2013. O desafio de adensar a cadeia de P&D 
de medicamentos biotecnológicos no Brasil. BNDES Setorial, 38, 173-211 
Pisano G, 2006. Science Business. The promise, the reality and the future of biotech. Harvard University Press. 
Boston. 
Quach U, Thorsteinsdóttir H, Renihan J, Bhatt A, Costa von A, Zoë Singer P A, Daar, Abdallah S, 
2006. Biotechnology patenting takes off in developing countries. International Journal of. Biotechnology, 
8( 1/2), 43. 
Ramani S, 2002. Who is interested in biotech? R&D strategies, knowledge base and market sales of 
Indian biopharmaceutical firms. Research Policy 31(3) 381–398. 
Reid S E, Ramani S V, 2012. The harnessing of biotechnology in India: Which roads to travel?. 
Technological Forecasting and Social Change, 79(4), 648-664. 
Reis C, Pieroni J P, Barros de Souza J, 2010. Biotecnologia para saúde no Brasil BNDES Setorial 32, 
193-230 
Brazilian Health Biotechnology Innovation System: an essay about the public policy rationale 
 
Carlos Bianchi 
 
 
Fronteiras: Journal of Social, Technological and Environmental Science • http://revistas.unievangelica.edu.br/index.php/fronteiras/  
v.5, n.1, jan.-jun. 2016 • p. 14-30. • DOI http://dx.doi.org/10.21664/2238-8869.2016v5i1.p14-30 • ISSN 2238-8869 
29 
 
Rezaie R, Frew S, Sammut S, Maliakkal M, Daar A, Singer P, 2008. Brazilian health biotech-fostering 
crosstalk between public and private sectors. Nature Biotechnology. 26(6). 
Sant'Ana P, Aucélio J G, 2006. Trinta anos de políticas públicas no Brasil para a área de biotecnologia. 
Parcerias Estratégicas, 11(23), 251-268. 
Thorsteinsdottir H, (Ed) 2012. South-South collaboration in health biotechnology: growing partnerships amongst 
developing countries. IDRC. New Delhi 
Thorsteinsdóttir H, Quach U, Martin D K, Daar A S, Singer P A, 2004. Introduction: promoting global 
health through biotechnology. Nature Biotechnology, 22, DC3-DC7. 
Torres Freire C E, 2014. Biotecnologia no Brasil: uma atividade econômica baseada em empresa, academia e Estado. 
Tese de Doutorado, FFLCH, Universidade de São Paulo, São Paulo. Available from: 
http://www.teses.usp.br/teses/disponiveis/8/8132/tde-14012015-180416/  
Vargas M, 2009 Documento setorial: farmacêutica. In: C G, Gadelha (Coord.), Projeto perspectivas do 
investimento no Brasil: sistema produtivo: complexo industrial da saúde. Rio de Janeiro: IE/UFRJ; IE/Unicamp. 
Vargas M, Bianchi C, 2013 Incorporação da rota biotecnológica na indústria farmacêutica brasileira: 
desafios e oportunidades. Relatório de Acompanhamento Setorial. Agência Brasileira de 
Desenvolvimento Industrial – ABDI. Brasilia. Available from: 
http://www.abdi.com.br/Estudo/relatorio_biofarmaceutica.pdf 
Watkins A, Papaioannou T, Mugwagwa J, Kale D, 2015. National innovation systems and the 
intermediary role of industry associations in building institutional capacities for innovation in 
developing countries: A critical review of the literature. Research Policy, 44(8), 1407-1418. 
Weltman W, 2002. A produção científica publicada pelo Instituto Oswaldo Cruz no período 1900-17: 
um estudo exploratório. História, Ciências, Saúde. 9(1):159-186 
 
O Sistema Brasileiro de Inovação em Saúde Humana: Um ensaio 
sobre a lógica das políticas públicas 
 
RESUMO 
O surgimento da biotecnologia é uma das transformações mais importantes dos sistemas de inovação 
em saúde. Este artigo visa discutir a lógica das políticas públicas de promoção da biotecnologia para 
saúde humana no Brasil no período 2004-2014. Com base num exaustivo trabalho de revisão 
documental e levantamento primário de dados, o artigo salienta como as políticas públicas brasileiras 
seguiram um roteiro de desigual acumulação, onde convivem diferentes fundamentações teóricas para 
as políticas, sejam elas explícitas ou implícitas. A análise conclui com a discussão dos limites das 
políticas publica, salientando duas dimensões que afetam o alcance das mesmas: i) a mudança na 
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orientação e na lógica das políticas, ii) que coloca novos desafios para a governança, os quais, por sua 
vez, requerem novas coordenações com outras políticas implícitas. 
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